ID

25975

Descrizione

Clinical Trial of SAHA in Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00416130

collegamento

https://clinicaltrials.gov/show/NCT00416130

Keywords

  1. 02/10/17 02/10/17 -
  2. 04/10/17 04/10/17 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

2 ottobre 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Breast Cancer NCT00416130

Eligibility Breast Cancer NCT00416130

Criteria
Descrizione

Criteria

cytologically or histologically confirmed adenocarcinoma of the breast that is recurrent and/or metastatic
Descrizione

Breast adenocarcinoma recurrent | Breast adenocarcinoma metastatic

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0861355
UMLS CUI [2]
C1697918
must have measurable disease as defined by recist criteria
Descrizione

Measurable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
no more than 2 prior chemotherapy for recurrent and/or metastatic disease excluding neoadjuvant or adjuvant chemotherapy
Descrizione

Chemotherapy Quantity Recurrent disease | Chemotherapy Quantity Neoplasm Metastasis | Exception Chemotherapy Neoadjuvant | Exception Adjuvant Chemotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0277556
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0027627
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0392920
UMLS CUI [3,3]
C0600558
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0085533
previously received anthracycline- and taxane-containing chemotherapy for treatment of breast cancer in the neoadjuvant, adjuvant, or metastatic setting
Descrizione

Chemotherapy Containing Anthracyclines | Chemotherapy Containing Taxane | Neoadjuvant Therapy Breast Carcinoma | Adjuvant therapy Breast Carcinoma | Secondary malignant neoplasm of female breast

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0332256
UMLS CUI [1,3]
C0282564
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0332256
UMLS CUI [2,3]
C0215136
UMLS CUI [3,1]
C0600558
UMLS CUI [3,2]
C0678222
UMLS CUI [4,1]
C0677850
UMLS CUI [4,2]
C0678222
UMLS CUI [5]
C0346993
must be able to swallow capsules
Descrizione

Able to swallow capsules

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2712086
UMLS CUI [1,2]
C0006935
adequate bone marrow reserve and liver function
Descrizione

Mature Neutrophils Present Bone Marrow Complete | Liver function

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1708947
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0205197
UMLS CUI [2]
C0232741
women in reproductive age group must agree to practice effective contraception during the entire study period unless documentation of infertility exists.
Descrizione

Childbearing Potential Contraceptive methods | Exception Documentation Infertility

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0175636
UMLS CUI [2,3]
C0021359
key exclusion criteria:
Descrizione

Exclusion Criteria Main

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
prior treatment with any hdac inhibitor. patients who have received such agents for other indications, e.g. epilepsy, may enroll in the trial after a 30 day washout period.
Descrizione

Histone deacetylase inhibitor | Histone deacetylase inhibitor Epilepsy allowed

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1512474
UMLS CUI [2,1]
C1512474
UMLS CUI [2,2]
C0014544
UMLS CUI [2,3]
C0683607
known cns involvement by tumor
Descrizione

Central Nervous System Involvement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C4050309
concurrent use of oral retinoids or any vitamin a, other than a single multivitamin tablet daily
Descrizione

Retinoids Oral | Vitamin A | Exception Daily Multivitamin Oral Tablet

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0035339
UMLS CUI [1,2]
C1527415
UMLS CUI [2]
C0042839
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0976064
acute infection requiring intravenous antibiotics or antifungal agents,known hiv infection, active hepatitis b and/or hepatitis c infection
Descrizione

Communicable Disease Requirement Intravenous antibiotic therapy | Communicable Disease Requirement Antifungal Agents | HIV Infection | Hepatitis B | Hepatitis C

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0559680
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C1514873
UMLS CUI [2,3]
C0003308
UMLS CUI [3]
C0019693
UMLS CUI [4]
C0019163
UMLS CUI [5]
C0019196
uncontrolled intercurrent illness
Descrizione

Comorbidity Uncontrolled

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
cancer other than breast cancer with the exception of basal cell carcinoma or disease that has been in remission for ≥5 years
Descrizione

Malignant Neoplasms | Exception Breast Carcinoma | Exception Basal cell carcinoma | Exception Disease remission Duration

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0678222
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0544452
UMLS CUI [4,3]
C0449238
pregnant or lactating women
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147

Similar models

Eligibility Breast Cancer NCT00416130

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Breast adenocarcinoma recurrent | Breast adenocarcinoma metastatic
Item
cytologically or histologically confirmed adenocarcinoma of the breast that is recurrent and/or metastatic
boolean
C0861355 (UMLS CUI [1])
C1697918 (UMLS CUI [2])
Measurable Disease
Item
must have measurable disease as defined by recist criteria
boolean
C1513041 (UMLS CUI [1])
Chemotherapy Quantity Recurrent disease | Chemotherapy Quantity Neoplasm Metastasis | Exception Chemotherapy Neoadjuvant | Exception Adjuvant Chemotherapy
Item
no more than 2 prior chemotherapy for recurrent and/or metastatic disease excluding neoadjuvant or adjuvant chemotherapy
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0277556 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0027627 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C0600558 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0085533 (UMLS CUI [4,2])
Chemotherapy Containing Anthracyclines | Chemotherapy Containing Taxane | Neoadjuvant Therapy Breast Carcinoma | Adjuvant therapy Breast Carcinoma | Secondary malignant neoplasm of female breast
Item
previously received anthracycline- and taxane-containing chemotherapy for treatment of breast cancer in the neoadjuvant, adjuvant, or metastatic setting
boolean
C0392920 (UMLS CUI [1,1])
C0332256 (UMLS CUI [1,2])
C0282564 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C0332256 (UMLS CUI [2,2])
C0215136 (UMLS CUI [2,3])
C0600558 (UMLS CUI [3,1])
C0678222 (UMLS CUI [3,2])
C0677850 (UMLS CUI [4,1])
C0678222 (UMLS CUI [4,2])
C0346993 (UMLS CUI [5])
Able to swallow capsules
Item
must be able to swallow capsules
boolean
C2712086 (UMLS CUI [1,1])
C0006935 (UMLS CUI [1,2])
Mature Neutrophils Present Bone Marrow Complete | Liver function
Item
adequate bone marrow reserve and liver function
boolean
C1708947 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C0232741 (UMLS CUI [2])
Childbearing Potential Contraceptive methods | Exception Documentation Infertility
Item
women in reproductive age group must agree to practice effective contraception during the entire study period unless documentation of infertility exists.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0175636 (UMLS CUI [2,2])
C0021359 (UMLS CUI [2,3])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Histone deacetylase inhibitor | Histone deacetylase inhibitor Epilepsy allowed
Item
prior treatment with any hdac inhibitor. patients who have received such agents for other indications, e.g. epilepsy, may enroll in the trial after a 30 day washout period.
boolean
C1512474 (UMLS CUI [1])
C1512474 (UMLS CUI [2,1])
C0014544 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
Central Nervous System Involvement
Item
known cns involvement by tumor
boolean
C4050309 (UMLS CUI [1])
Retinoids Oral | Vitamin A | Exception Daily Multivitamin Oral Tablet
Item
concurrent use of oral retinoids or any vitamin a, other than a single multivitamin tablet daily
boolean
C0035339 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0042839 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0976064 (UMLS CUI [3,2])
Communicable Disease Requirement Intravenous antibiotic therapy | Communicable Disease Requirement Antifungal Agents | HIV Infection | Hepatitis B | Hepatitis C
Item
acute infection requiring intravenous antibiotics or antifungal agents,known hiv infection, active hepatitis b and/or hepatitis c infection
boolean
C0009450 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0559680 (UMLS CUI [1,3])
C0009450 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0003308 (UMLS CUI [2,3])
C0019693 (UMLS CUI [3])
C0019163 (UMLS CUI [4])
C0019196 (UMLS CUI [5])
Comorbidity Uncontrolled
Item
uncontrolled intercurrent illness
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Malignant Neoplasms | Exception Breast Carcinoma | Exception Basal cell carcinoma | Exception Disease remission Duration
Item
cancer other than breast cancer with the exception of basal cell carcinoma or disease that has been in remission for ≥5 years
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0544452 (UMLS CUI [4,2])
C0449238 (UMLS CUI [4,3])
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial